Trial Profile
A real-world retrospective cohort study evaluating suicidal behavior associated with the use of lisdexamfetamine dimesylate and other stimulant treatments for attention-deficit/hyperactivity disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 21 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management